Heart failure & cardiomyopathiesRandomised controlled trial
Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF
- Cost-effectiveness analysis (Markov model) based on the SOLOIST-WHF randomised trial
- lifetime horizon
- US health care sector perspective
Costs from the National Inpatient Sample; life expectancy from census data modified by SOLOIST-WHF mortality; event rates carried forward from trial; utility from published reports
Authors' conclusion
In patients with diabetes and recent worsening of heart failure, sotagliflozin is cost-effective in the U.S. using commonly accepted willingness-to-pay thresholds.
Study context
- Population
- Patients with diabetes and recent worsening of HFSOLOIST-WHF trial data
- Participants
- 1,222 patients
- Comparison
- Sotagliflozin vs placebo
- Primary endpoint
- Cost-effectiveness (lifetime QALYs, costs, incremental cost-effectiveness ratio)
- Follow-up
- Lifetime
Primary result
As reported in the abstract
Lifetime QALYs and costs
| Group | Lifetime quality-adjusted life-years (QALYs) | Lifetime costs |
|---|---|---|
| Sotagliflozin | 4.43 | $220,113 |
| Placebo | 4.04 | $188,198 |
- Point estimate incremental cost-effectiveness ratio
- $81,823 per QALY gained
- Probability of being cost-effective at WTP $50,000 per QALY gained
- 3.6%
- Probability of being cost-effective at WTP $100,000 per QALY gained
- 67.5%
- Probability of being cost-effective at WTP $150,000 per QALY gained
- 89.4%
Further findings
Probability of being cost-effective by willingness-to-pay threshold
- $50,000 per QALY gained
- 3.6%
- $100,000 per QALY gained
- 67.5%
- $150,000 per QALY gained
- 89.4%
Original publication
Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF. JACC Heart Fail. Published 12 June 2024. doi:10.1016/j.jchf.2024.04.018
Summarised from the published abstract; every number is checked against it